Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $476.98 in the prior trading day, HCA Healthcare Inc (NYSE: HCA) closed at $469.79, down -1.51%. In other words, the price has decreased by -$1.51 from its previous closing price. On the day, 1.43 million shares were traded. HCA stock price reached its highest trading level at $480.87 during the session, while it also had its lowest trading level at $463.94.
Ratios:
Our goal is to gain a better understanding of HCA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 98.26 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.24. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.85.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 05 ’25 when McAlevey Michael R sold 3,892 shares for $473.79 per share. The transaction valued at 1,843,991 led to the insider holds 3,487 shares of the business.
Michael R McAlevey bought 3,892 shares of HCA for $1,843,991 on Nov 05 ’25. On Sep 08 ’25, another insider, Cuffe Michael S., who serves as the Officer of the company, bought 3,836 shares for $418.84 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCA now has a Market Capitalization of 109927809024 and an Enterprise Value of 155637219328. As of this moment, HCA’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.16, and their Forward P/E ratio for the next fiscal year is 15.75. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.44. Its current Enterprise Value per Revenue stands at 2.093 whereas that against EBITDA is 10.306.
Stock Price History:
The Beta on a monthly basis for HCA is 1.37, which has changed by 0.59445095 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, HCA has reached a high of $520.00, while it has fallen to a 52-week low of $289.98. The 50-Day Moving Average of the stock is 0.92%, while the 200-Day Moving Average is calculated to be 19.36%.
Shares Statistics:
The stock has traded on average 1.36M shares per day over the past 3-months and 1338430 shares per day over the last 10 days, according to various share statistics. A total of 229.85M shares are outstanding, with a floating share count of 156.36M. Insiders hold about 31.48% of the company’s shares, while institutions hold 62.81% stake in the company. Shares short for HCA as of 1764288000 were 4928210 with a Short Ratio of 3.63, compared to 1761868800 on 4019017. Therefore, it implies a Short% of Shares Outstanding of 4928210 and a Short% of Float of 3.1300000000000003.
Dividends & Splits
In the trailing 12 months, HCA’s forward annual dividend rate was 2.82, compared to 2.88 this year. Against a Trailing Annual Dividend Yield of 0.0059121973. The stock’s 5-year Average Dividend Yield is 0.75.
Earnings Estimates
The market rating for HCA Healthcare Inc (HCA) is a result of the insights provided by 20.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $7.2, with high estimates of $7.6 and low estimates of $6.78.
Analysts are recommending an EPS of between $27.92 and $27.4 for the fiscal current year, implying an average EPS of $27.69. EPS for the following year is $29.81, with 22.0 analysts recommending between $31.42 and $27.77.
Revenue Estimates
19 analysts predict $19.67B in revenue for. The current quarter. It ranges from a high estimate of $20.05B to a low estimate of $19.26B. As of. The current estimate, HCA Healthcare Inc’s year-ago sales were $18.29BFor the next quarter, 19 analysts are estimating revenue of $19.18B. There is a high estimate of $19.42B for the next quarter, whereas the lowest estimate is $18.61B.
A total of 22 analysts have provided revenue estimates for HCA’s current fiscal year. The highest revenue estimate was $76.14B, while the lowest revenue estimate was $75.13B, resulting in an average revenue estimate of $75.73B. In the same quarter a year ago, actual revenue was $70.6BBased on 21 analysts’ estimates, the company’s revenue will be $79.15B in the next fiscal year. The high estimate is $80.6B and the low estimate is $77B.
